Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1986-03-07
1991-07-30
Griffin, Ronald W.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
514 15, 514 17, 514400, 514912, 548336, 548337, 548342, A61K 31475, A61K 3113, A61K 3154
Patent
active
050360485
ABSTRACT:
A method and composition for reducing and/or controlling elevated intraocular pressure, especially the elevated intraocular pressure associated with glaucoma, are disclosed in which an angiotensin II antagonist is administered to the eye.
REFERENCES:
patent: 3932624 (1976-01-01), Fulton
patent: 4179433 (1979-12-01), Kisfaludy et al.
patent: 4340598 (1982-07-01), Furukawa
patent: 4355040 (1982-11-01), Furukawa
patent: 4444778 (1984-04-01), Coughlin
patent: 4515800 (1985-05-01), Cavero et al.
patent: 4517199 (1985-05-01), York, Jr.
patent: 4616012 (1986-10-01), Neustadt et al.
D. Regoli and J. R. Vane, A Sensitive Method for the Assay of Angiotensin, Brit. J. Pharmacol. (1964), 23, pp. 351-359.
A. D. T. Pals et al., A Specific Competitive Antagonist of the Vascular Action of Angiotensin II, Circulation Research Vol. XXIX, Dec. 1971, pp. 664-672.
R. R. Luther et al., Renin Inhibitors: Specific Modulators of the Renin-Angiotensin System, Arzneim-Forsch./Drug Res. 39 (1), Nr. 1 (1989), pp. 1-5.
Miguel A. Ondetti et al., Inhibition of the Renin-Angiotensin System, A New Approach to the Therapy of Hypertension, Journal of Medicinal Chemistry, vol. 24, No. 4, 4/81, pp. 355-361.
Kel Buhshan Anand et al., Systemic Effects of Ophthalmic Medication in the Elderly, New York State Journal of Medicine, Mar. 1988, pp. 134-136.
Remington's Pharmaceutical Sciences, Arthur Osol editor, 16th Ed. Mack Publishing Co., Easton, Pa., 1980, p. 783.
Stedman's Medical Dictionary, 23rd ed., The Williams & Wilkins Co., Baltimore, Md. 1976, pp. 586 and 203.
The Merck Index, 9th ed., Merck & Co., Inc., Rahway, N.J., 1976, pp. 170 and 2899-2900.
Ionitescu C., Rev. Chir. (Oftalmol), 26(2), 137-138, (1982).
Duncia et al., "The Discovery of Patent Nonpeptide Angiotension II Receptor Antagonists: A New Class of Potent Antihypertensives", J. Med. Chem., 1990, 33, pp. 1312-1329.
Carini et al., "Nonpeptide Angiotension II Receptor Antagonists: N-[Benzyloxy)benzyl]Imidazoles and Related Compounds as Potent Antipertensives", J. Med. Chem., 1990, 33, pp. 1330-1336.
Chiu et al., "Nonpeptide Angiotension II Receptor Antagonists, VII, Cellular and Biochemical Pharmacology of DuP753, an Orally Active Antihypertensive Agent", The Journal of Pharmacology and Experimental Therapeutics, (1990), vol. 252, No. 2, pp. 711-718.
Wong et al., "Nonpeptide Angiotension II Receptor Antagonists, VIII, Characterization of Functional Antagonism Displayed by DuP753, an Orally Active Antihypertensive Agent", The Journal of Pharmacology and Experimental Theraputics, (1990), vol. 252, No. 2, pp. 719-725.
Griffin Ronald W.
Majka Joseph T.
Nelson James R.
Rosen Gerald S.
Schering Corporation
LandOfFree
Angiotensin II receptor blockers as antiglaucoma agents does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Angiotensin II receptor blockers as antiglaucoma agents, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Angiotensin II receptor blockers as antiglaucoma agents will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1542667